Literature DB >> 27836056

Vaccination in Primary Immunodeficiency Disorders.

Ali Sobh1, Francisco A Bonilla2.   

Abstract

Immunocompromised patients have increased susceptibility to vaccine-preventable infections. Thus, vaccination is a critical issue in this population. Vaccines are usually classified as live versus inactivated or subunit (nonviable) vaccines. In general, inactivated vaccines are safe in immunocompromised patients and should be given per the routine schedule except when they are unlikely to have any benefit as in severe antibody deficiency or combined immunodeficient patients and patients receiving immunosuppressive therapy or immunoglobulin replacement. However, viable vaccines usually carry the risk of causing disease, especially in severely immunocompromised patients. Therefore, much greater caution must be exercised with the use of viable vaccines and administration is individualized on the basis of the estimated risk of infections if not vaccinated versus the potential adverse effects of the vaccine itself. In this review, we make clear recommendations on the basis of available evidence regarding both routine and specialized vaccines, viable and nonviable, and the degree of immune compromise in all the categories of immunodeficiency disorders.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune dysregulation; Inactivated vaccines; Live vaccines; Primary immunodeficiency; Vaccination

Mesh:

Substances:

Year:  2016        PMID: 27836056     DOI: 10.1016/j.jaip.2016.09.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  29 in total

Review 1.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 2.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

3.  A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004-2017).

Authors:  Qinhua Zhou; Xiaoying Hui; Wenjing Ying; Jia Hou; Wenjie Wang; Danru Liu; Ying Wang; Yeheng Yu; Jingyi Wang; Jinqiao Sun; Qian Zhang; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2018-03-20       Impact factor: 8.317

4.  Primary Immunodeficiency: New Insights and Practical Clinical Approaches.

Authors:  Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

Review 5.  Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).

Authors:  Jan F Mieves; Kirsten Wittke; Helma Freitag; Hans-Dieter Volk; Carmen Scheibenbogen; Leif G Hanitsch
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-05       Impact factor: 4.806

6.  Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients.

Authors:  Jacqueline Squire; Dr Avni Joshi
Journal:  Ann Allergy Asthma Immunol       Date:  2021-05-19       Impact factor: 6.347

Review 7.  Vaccination of immune compromised children-an overview for physicians.

Authors:  Laure F Pittet; Klara M Posfay-Barbe
Journal:  Eur J Pediatr       Date:  2021-03-05       Impact factor: 3.183

8.  Diagnosing inborn error of immunity following the presentation of a complicated acquired infection after MMRV vaccine administration.

Authors:  Lama AlZoebie; Hend Al Sereidi; Shaima Al Maeeni; Musaab Ramsi
Journal:  BMJ Case Rep       Date:  2020-01-21

Review 9.  Vaccination in PADs.

Authors:  Cinzia Milito; Valentina Soccodato; Giulia Collalti; Alison Lanciarotta; Ilaria Bertozzi; Marcello Rattazzi; Riccardo Scarpa; Francesco Cinetto
Journal:  Vaccines (Basel)       Date:  2021-06-09

10.  The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.

Authors:  Ailsa Robbins; Mathilde Bahuaud; Maxime Hentzien; Quentin Maestraggi; Coralie Barbe; Delphine Giusti; Richard Le Naour; Frederic Batteux; Amélie Servettaz
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.